Key Stats for Tilray Stock
- Price Change for Tilray stock: 44%
- $TLRY Share Price as of Dec. 12: $12.15
- 52-Week High: $23.30
- $TLRY Stock Price Target: $16.17
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Tilray (TLRY) stock exploded on Friday alongside the broader cannabis sector after reports emerged that President Donald Trump plans to reclassify marijuana at the federal level.
The White House is preparing an executive order that could come as soon as Monday, moving cannabis from Schedule I (alongside heroin) to the less restrictive Schedule III category (alongside steroids and Tylenol with codeine).
The rally was dramatic. Tilray stock jumped more than 44%, while rival Canopy Growth surged over 52%. The Amplify Seymour Cannabis ETF posted its best day on record with a 54% gain.
This momentum built throughout Friday’s trading session, notably after CNBC confirmed the White House’s plans with sources familiar with the matter.
Tilray CEO Irwin Simon captured the industry’s mood, telling CNBC he’s “a lot more optimistic than I ever have been.”
That sentiment reflects years of waiting for federal action that could finally transform the economics of the cannabis business.
See analysts’ growth forecasts and price targets for Tilray stock (It’s free!) >>>
What the Market Is Telling Us About Tilray Stock
The market reaction shows investors believe this regulatory shift will be a game-changer for cannabis companies.
Under current rules, marijuana businesses operate under Section 280E of the tax code, which prevents them from deducting normal business expenses because cannabis remains a Schedule I substance. Reclassification would eliminate this burden and dramatically improve profitability.
Banking restrictions have also kept cannabis companies from accessing traditional financial services. Schedule III status could unlock loans, credit card processing, and eventually listings on major US exchanges.
For companies like Tilray, which have struggled with heavy losses and tight capital markets, this would be transformative.
Analysts at Compass Point called the move “not an if, but a when,” and expect the Drug Enforcement Administration to finalize the reclassification by summer if Trump issues the order.
Roth’s Bill Kirk is also watching whether the Supreme Court takes up a case involving state versus federal cannabis regulations, which could further accelerate the timeline.
Global legal cannabis sales are projected to reach $40.5 billion in 2026, growing roughly 6% annually. The US accounts for 83% of that market, but Europe is emerging as the next growth frontier as countries roll out consistent regulatory frameworks.
Tilray has been building its medical cannabis presence in these higher-margin international markets.
Still, investors should stay grounded even as cannabis stocks trade at deep discounts for a reason. The sector remains highly competitive, pricing pressure is real, and access to capital has been limited.
Tilray stock peaked above $2,140 (adjusted for splits) in 2018 and now trades around $10. Reclassification isn’t full legalization, and the industry will need to keep pushing Congress for broader reforms around safety, access, and criminal justice.
But Friday’s surge shows the market sees this as the beginning of something bigger. Cannabis-focused attorney Shawn Hauser called it “the beginning of a new era of public health policy” that could dismantle “nearly a century of outdated drug policies.”
For Tilray stock and the cannabis sector, 2026 might finally deliver the credible catalysts this industry has been waiting for.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Tilray Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
